Endonovo Therapeutics (ENDV) Total Current Liabilities (2016 - 2023)
Endonovo Therapeutics has reported Total Current Liabilities over the past 13 years, most recently at $23.7 million for Q3 2023.
- Quarterly results put Total Current Liabilities at $23.7 million for Q3 2023, up 12.96% from a year ago — trailing twelve months through Sep 2023 was $23.7 million (up 12.96% YoY), and the annual figure for FY2022 was $33.4 million, up 88.58%.
- Total Current Liabilities for Q3 2023 was $23.7 million at Endonovo Therapeutics, up from $23.1 million in the prior quarter.
- Over the last five years, Total Current Liabilities for ENDV hit a ceiling of $33.4 million in Q4 2022 and a floor of $14.1 million in Q1 2020.
- Median Total Current Liabilities over the past 5 years was $19.8 million (2019), compared with a mean of $20.1 million.
- Biggest five-year swings in Total Current Liabilities: dropped 28.77% in 2020 and later soared 88.58% in 2022.
- Endonovo Therapeutics' Total Current Liabilities stood at $23.6 million in 2019, then decreased by 28.77% to $16.8 million in 2020, then increased by 5.21% to $17.7 million in 2021, then skyrocketed by 88.58% to $33.4 million in 2022, then dropped by 29.01% to $23.7 million in 2023.
- The last three reported values for Total Current Liabilities were $23.7 million (Q3 2023), $23.1 million (Q2 2023), and $25.5 million (Q1 2023) per Business Quant data.